Here, we extend current knowledge by demonstrating that down-regulation of PD-L1 by EGFR inhibitors is not restricted to lung cancer cell lines carrying sensitizing EGFR mutations, but also observed in lung cancer cell lines with wild type EGFR in a wide range of sensitivity to EGFR inhibitors (e.g. H441), and that EGFR inhibitors abrogate the IFNγ-induced overexpression of PD-L1 without adversely affecting the expression of antigen presenting molecules in lung cancer cell lines. Here, IFNG is linked to lung cancer.